The Journal of Immunology, Vol 144, Issue 1 251-258, Copyright © 1990 by American Association of Immunologists

ARTICLES

Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin

FJ Dumont, MJ Staruch, SL Koprak, MR Melino and NH Sigal
Department of Immunology Research, Merck Sharp and Dohme Research Laboratories, Rahway, NJ 07065.

FK-506 and the structurally related macrolide rapamycin (RAP) were investigated in comparison with cyclosporin A (CsA) for their immunosuppressive effects on murine T cells. All three agents suppressed the proliferation of splenic T cells triggered by lectins or antibodies to CD3 and Ly-6C. FK-506 or CsA also inhibited proliferation, IL-2 production, and IL-2R expression in splenic T cells activated with ionomycin + PMA. However, RAP minimally affected IL-2 production and IL-2R expression in these cells, although it reduced proliferation. Similarly, FK-506 and CsA, but not RAP, suppressed IL-2 production by activated DO.11.10 T hybridoma cells. In such a system, as well as in normal T cells stimulated with high ionomycin concentrations, FK-506 and CsA enhanced proliferation, indicating that they both abrogate negative signals associated with T cell activation. On the contrary, RAP diminished the autonomous proliferation of hybridoma cells, whereas FK-506 and CsA had little effect. The proliferative response induced in D10.G4 cells by IL-1 + ionomycin but not that induced by IL-1 + PMA was sensitive to inhibition by FK-506 and CsA. In contrast, RAP inhibited equally well both types of stimulation. Finally, T cell proliferation driven by IL-2 or IL-4 was found to be relatively resistant to FK-506 or CsA but sensitive to RAP. Altogether, these data demonstrate that FK-506 and CsA alter similar calcium-associated events of T cell activation and block T cell proliferation primarily by suppressing lymphokine production. RAP interferes with a different set of events and inhibits T cells by impairing their response to growth-promoting lymphokines.

This article has been cited by other articles:

				N. Oshiro, R. Takahashi, K.-i. Yoshino, K. Tanimura, A. Nakashima, S. Eguchi, T. Miyamoto, K. Hara, K. Takehana, J. Avruch, et al. The Proline-rich Akt Substrate of 40 kDa (PRAS40) Is a Physiological Substrate of Mammalian Target of Rapamycin Complex 1 J. Biol. Chem., July 13, 2007; 282(28): 20329 - 20339. [Abstract] [Full Text] [PDF]

				G Alperovich, I Rama, N Lloberas, M Franquesa, R Poveda, M Goma, I Herrero-Fresneda, J M Cruzado, N Bolanos, M Carrera, et al. New immunosuppresor strategies in the treatment of murine lupus nephritis Lupus, January 1, 2007; 16(1): 18 - 24. [Abstract] [PDF]

				M. Battaglia, A. Stabilini, and M.-G. Roncarolo Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells Blood, June 15, 2005; 105(12): 4743 - 4748. [Abstract] [Full Text] [PDF]

				C. M. Cham and T. F. Gajewski Glucose Availability Regulates IFN-{gamma} Production and p70S6 Kinase Activation in CD8+ Effector T Cells J. Immunol., April 15, 2005; 174(8): 4670 - 4677. [Abstract] [Full Text] [PDF]

				Y. Zhang, F. Erdmann, R. Baumgrass, M. Schutkowski, and G. Fischer Unexpected Side Chain Effects at Residue 8 of Cyclosporin A Derivatives Allow Photoswitching of Immunosuppression J. Biol. Chem., February 11, 2005; 280(6): 4842 - 4850. [Abstract] [Full Text] [PDF]

				C. J. Fox, P. S. Hammerman, and C. B. Thompson The Pim kinases control rapamycin-resistant T cell survival and activation J. Exp. Med., January 18, 2005; 201(2): 259 - 266. [Abstract] [Full Text] [PDF]

				M. W. Harding Immunophilins, mTOR, and Pharmacodynamic Strategies for a Targeted Cancer Therapy: Commentary re: J. M. Peralba et al., Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clin. Cancer Res., 9: 2887-2892, 2003. Clin. Cancer Res., August 1, 2003; 9(8): 2882 - 2886. [Full Text] [PDF]

				P. Dupont and A.N. Warrens The evolving role of sirolimus in renal transplantation QJM, June 1, 2003; 96(6): 401 - 409. [Full Text] [PDF]

				M. Mayerhofer, P. Valent, W. R. Sperr, J. D. Griffin, and C. Sillaber BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha , through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin Blood, November 15, 2002; 100(10): 3767 - 3775. [Abstract] [Full Text] [PDF]

				J. Roy, J.-S. Paquette, J.-F. Fortin, and M. J. Tremblay The Immunosuppressant Rapamycin Represses Human Immunodeficiency Virus Type 1 Replication Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3447 - 3455. [Abstract] [Full Text] [PDF]

				H. Matsue, C. Yang, K. Matsue, D. Edelbaum, M. Mummert, and A. Takashima Contrasting Impacts of Immunosuppressive Agents (Rapamycin, FK506, Cyclosporin A, and Dexamethasone) on Bidirectional Dendritic Cell-T Cell Interaction During Antigen Presentation J. Immunol., October 1, 2002; 169(7): 3555 - 3564. [Abstract] [Full Text] [PDF]

				T. Yoshii, S. Magara, D. Miyai, E. Kuroki, H. Nishimura, S. Furudoi, and T. Komori Inhibitory effect of roxithromycin on the local levels of bone-resorbing cytokines in an experimental model of murine osteomyelitis J. Antimicrob. Chemother., August 1, 2002; 50(2): 289 - 292. [Abstract] [Full Text] [PDF]

				A. Grolleau, J. Bowman, B. Pradet-Balade, E. Puravs, S. Hanash, J. A. Garcia-Sanz, and L. Beretta Global and Specific Translational Control by Rapamycin in T Cells Uncovered by Microarrays and Proteomics J. Biol. Chem., June 14, 2002; 277(25): 22175 - 22184. [Abstract] [Full Text] [PDF]

				L.-H. Zhang, H.-D. Youn, and J. O. Liu Inhibition of Cell Cycle Progression by the Novel Cyclophilin Ligand Sanglifehrin A Is Mediated through the NFkappa B-dependent Activation of p53 J. Biol. Chem., November 16, 2001; 276(47): 43534 - 43540. [Abstract] [Full Text] [PDF]

				S. O. Marx and A. R. Marks Bench to Bedside: The Development of Rapamycin and Its Application to Stent Restenosis Circulation, August 21, 2001; 104(8): 852 - 855. [Full Text] [PDF]

				G. Zenke, U. Strittmatter, S. Fuchs, V. F. J. Quesniaux, V. Brinkmann, W. Schuler, M. Zurini, A. Enz, A. Billich, J.-J. Sanglier, et al. Sanglifehrin A, a Novel Cyclophilin-Binding Compound Showing Immunosuppressive Activity with a New Mechanism of Action J. Immunol., June 15, 2001; 166(12): 7165 - 7171. [Abstract] [Full Text] [PDF]

				L.-H. Zhang and J. O. Liu Sanglifehrin A, a Novel Cyclophilin-Binding Immunosuppressant, Inhibits IL-2-Dependent T Cell Proliferation at the G1 Phase of the Cell Cycle J. Immunol., May 1, 2001; 166(9): 5611 - 5618. [Abstract] [Full Text] [PDF]

				W. Y. Almawi and O. K. Melemedjian Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A Nephrol. Dial. Transplant., December 1, 2000; 15(12): 1916 - 1918. [Full Text] [PDF]

				L. W. Kraiss, A. S. Weyrich, N. M. Alto, D. A. Dixon, T. M. Ennis, V. Modur, T. M. McIntyre, S. M. Prescott, and G. A. Zimmerman Fluid flow activates a regulator of translation, p70/p85 S6 kinase, in human endothelial cells Am J Physiol Heart Circ Physiol, May 1, 2000; 278(5): H1537 - H1544. [Abstract] [Full Text] [PDF]

				P. Hollsberg Mechanisms of T-Cell Activation by Human T-Cell Lymphotropic Virus Type I Microbiol. Mol. Biol. Rev., June 1, 1999; 63(2): 308 - 333. [Abstract] [Full Text] [PDF]

				A. Algeciras-Schimnich, T. S. Griffith, D. H. Lynch, and C. V. Paya Cell Cycle-Dependent Regulation of FLIP Levels and Susceptibility to Fas-Mediated Apoptosis J. Immunol., May 1, 1999; 162(9): 5205 - 5211. [Abstract] [Full Text] [PDF]

				J. Longoria, R. F. Roberts, C. C. Marboe, B. C. Stouch, V. A. Starnes, and M. L. Barr SIROLIMUS (RAPAMYCIN) POTENTIATES CYCLOSPORINE IN PREVENTION OF ACUTE LUNG REJECTION J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 714 - 718. [Abstract] [Full Text] [PDF]

				J. D. Powell, C. G. Lerner, and R. H. Schwartz Inhibition of Cell Cycle Progression by Rapamycin Induces T Cell Clonal Anergy Even in the Presence of Costimulation J. Immunol., March 1, 1999; 162(5): 2775 - 2784. [Abstract] [Full Text] [PDF]

				S. M. Belkowski, C. S. Rubin, and M. B. Prystowsky Isolation and Analysis of a T Cell Clone Variant Exhibiting Constitutively Phosphorylated Ser133 cAMP Response Element-Binding Protein J. Immunol., July 15, 1998; 161(2): 659 - 665. [Abstract] [Full Text] [PDF]

				X. C. Li, P. Roy-Chaudhury, W. W. Hancock, R. Manfro, M. S. Zand, Y. Li, X. X. Zheng, P. W. Nickerson, J. Steiger, T. R. Malek, et al. IL-2 and IL-4 Double Knockout Mice Reject Islet Allografts: A Role for Novel T Cell Growth Factors in Allograft Rejection J. Immunol., July 15, 1998; 161(2): 890 - 896. [Abstract] [Full Text] [PDF]

				S. Inui, H. Sanjo, K. Maeda, H. Yamamoto, E. Miyamoto, and N. Sakaguchi Ig Receptor Binding Protein 1 (alpha 4) Is Associated With a Rapamycin-Sensitive Signal Transduction in Lymphocytes Through Direct Binding to the Catalytic Subunit of Protein Phosphatase 2A Blood, July 15, 1998; 92(2): 539 - 546. [Abstract] [Full Text] [PDF]

				B. R. Blazar, P. A. Taylor, A. Panoskaltsis-Mortari, and D. A. Vallera Rapamycin Inhibits the Generation of Graft-Versus-Host Disease- and Graft-Versus-Leukemia-Causing T Cells by Interfering with the Production of Th1 or Th1 Cytotoxic Cytokines J. Immunol., June 1, 1998; 160(11): 5355 - 5365. [Abstract] [Full Text] [PDF]

				F. J. Dumont, M. J. Staruch, P. Fischer, C. DaSilva, and R. Camacho Inhibition of T Cell Activation by Pharmacologic Disruption of the MEK1/ERK MAP Kinase or Calcineurin Signaling Pathways Results in Differential Modulation of Cytokine Production J. Immunol., March 15, 1998; 160(6): 2579 - 2589. [Abstract] [Full Text] [PDF]

				M. L. Boytim, S.-C. Lyu, R. Jung, A. M. Krensky, and C. Clayberger Inhibition of Cell Cycle Progression by a Synthetic Peptide Corresponding to Residues 65-79 of an HLA Class II Sequence: Functional Similarities but Mechanistic Differences with the Immunosuppressive Drug Rapamycin J. Immunol., March 1, 1998; 160(5): 2215 - 2222. [Abstract] [Full Text] [PDF]

				K. W. Mollison, T. A. Fey, R. A. Krause, J. M. Andrews, P. T. Bretheim, J. A. Brandt, M. Kawai, R. Wagner, G. C. Hsieh, and J. R. Luly Discovery of Less Nephrotoxic FK506 Analogs and Determining Immunophilin Dependence of Immunosuppressant Nephrotoxicity with a Novel Single-Dose Rat Cisplatin Potentiation Assay J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1509 - 1519. [Abstract] [Full Text]

				J. B. Crawley, L. Rawlinson, F. V. Lali, T. H. Page, J. Saklatvala, and B. M. J. Foxwell T Cell Proliferation in Response to Interleukins 2 and 7 Requires p38MAP Kinase Activation J. Biol. Chem., June 6, 1997; 272(23): 15023 - 15027. [Abstract] [Full Text] [PDF]

				D. A. Hess, I. A. Bird, W. Y. Almawi, and M. J. Rieder The Hydroxylamine of Sulfamethoxazole Synergizes with FK506 and Cyclosporin A, Inhibiting T-Cell Proliferation J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 540 - 548. [Abstract] [Full Text]

				J. B. Crawley, L. M. Williams, T. Mander, F. M. Brennan, and B. M.J. Foxwell Interleukin-10 Stimulation of Phosphatidylinositol 3-Kinase and p70 S6 Kinase Is Required for the Proliferative but Not the Antiinflammatory Effects of the Cytokine J. Biol. Chem., July 5, 1996; 271(27): 16357 - 16362. [Abstract] [Full Text] [PDF]

				E. Kaftan, A. R. Marks, and B. E. Ehrlich Effects of Rapamycin on Ryanodine Receptor/Ca2+-Release Channels From Cardiac Muscle Circ. Res., June 1, 1996; 78(6): 990 - 997. [Abstract] [Full Text]

				M. C. Lorenz and J. Heitman TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin J. Biol. Chem., November 17, 1995; 270(46): 27531 - 27537. [Abstract] [Full Text] [PDF]

				C. Petritsch, Rüd. Woscholski, H. M. L. Edelmann, and L. M. Ballou Activation of p70 S6 Kinase and erk-encoded Mitogen-activated Protein Kinases Is Resistant to High Cyclic Nucleotide Levels in Swiss 3T3 Fibroblasts J. Biol. Chem., November 3, 1995; 270(44): 26619 - 26625. [Abstract] [Full Text] [PDF]

				D. M. Sabatini, B. A. Pierchala, R. K. Barrow, M. J. Schell, and S. H. Snyder The Rapamycin and FKBP12 Target (RAFT) Displays Phosphatidylinositol 4-Kinase Activity J. Biol. Chem., September 8, 1995; 270(36): 20875 - 20878. [Abstract] [Full Text] [PDF]

				D. Price, Grove JR, V Calvo, J Avruch, and B. Bierer Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase Science, August 14, 1992; 257(5072): 973 - 977. [Abstract] [PDF]

				J Heitman, N. Movva, and M. Hall Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast Science, August 23, 1991; 253(5022): 905 - 909. [Abstract] [PDF]

				S. Schreiber Chemistry and biology of the immunophilins and their immunosuppressive ligands Science, January 18, 1991; 251(4991): 283 - 287. [Abstract] [PDF]

				B. Bierer, P. Somers, T. Wandless, S. Burakoff, and S. Schreiber Probing immunosuppressant action with a nonnatural immunophilin ligand Science, October 26, 1990; 250(4980): 556 - 559. [Abstract] [PDF]

				K. England, J. Watson, G. Beale, M. Warner, J. Cross, and M. Rumsby Signalling Pathways Regulating the Dephosphorylation of Ser729 in the Hydrophobic Domain of Protein Kinase Cepsilon upon Cell Passage J. Biol. Chem., March 23, 2001; 276(13): 10437 - 10442. [Abstract] [Full Text] [PDF]